Investments and Other Assets - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Schedule of Equity Method Investments [Line Items]
Investments and other assets	$ 44,264	$ 42,883
Change in fair value of investments, net	(32,565)	0	$ 0
Collaboration revenue	57,877	36,275	52,121
Accrued expenses	55,355	67,017
AvenCell Therapeutics, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Reclassification of other comprehensive income (loss) - equity method investment	2,100
Kyverna Therapeutics Inc [Member]
Schedule of Equity Method Investments [Line Items]
Investment Owned, Balance, Principal Amount	4,400
Change in fair value of investments, net	5,600
Investment Owned, Fair Value		10,000	10,000
Collaboration revenue	0	0
AvenCell [Member]
Schedule of Equity Method Investments [Line Items]
Investments and other assets	7,900
Change in fair value of investments, net	27,000
Investment Owned, Fair Value	7,900	11,800
Collaboration revenue	21,000	13,200	22,800
Accounts receivable	0	$ 0
AvenCell [Member] | AvenCell Therapeutics, Inc. [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		33.33%
Sparing Vision [Member]
Schedule of Equity Method Investments [Line Items]
Investments and other assets	14,600	$ 14,600
Investment Owned, Fair Value	14,600	14,800
Collaboration revenue	$ 2,500	$ 1,800	$ 200